Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors

Abstract

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

1 . A method of treating hyperlipidemia in a mammal in need of such treatment comprising administering a therapeutically-effective amount of compound of the chemical formula: 
       
         
           
           
               
               
           
         
         wherein 
       
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, to the mammal. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of lithium, sodium, potassium, calcium, magnesium, zinc, aluminium, amino acid, ammonium, mono-alkyl ammonium, dialkyl ammonium, trialkyl ammonium and N-methyl glucamine. 
     
     
         3 . The method of  claim 1 , wherein the compound is administered as a pharmaceutical composition comprising the compound together with a pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         4 . The method of  claim 3 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         5 . The method of  claim 3 , wherein the pharmaceutical composition is formulated as an oral tablet. 
     
     
         6 . A method of treating hypertriglyceridemia in a mammal in need of such treatment comprising administering a therapeutically-effective amount of compound of the chemical formula: 
       
         
           
           
               
               
           
         
       
       wherein 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, to the mammal. 
     
     
         7 . The method of  claim 6 , wherein the pharmaceutically acceptable salt is selected from the group consisting of lithium, sodium, potassium, calcium, magnesium, zinc, aluminium, amino acid, ammonium, mono-alkyl ammonium, dialkyl ammonium, trialkyl ammonium and N-methyl glucamine. 
     
     
         8 . The method of  claim 6 , wherein the compound is administered as a pharmaceutical composition comprising the compound together with a pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         9 . The method of  claim 8 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         10 . The method of  claim 8 , wherein the pharmaceutical composition is formulated as an oral tablet.